Related Experiment Video
Updated: May 12, 2026

An In Vitro Skin Irritation Test SIT using the EpiDerm Reconstructed Human Epidermal RHE Model
Published on: July 13, 2009
GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance
Shashikiran Donthamsetty1, Andy Forreryd2, Paul Sterchele1
1International Flavors & Fragrances, Hazlet, NJ, USA.
Abstract:
Development of New Approach Methodologies (NAMs) capable of providing a No Expected Sensitization Induction Level (NESIL) value remains a high priority for the fragrance industry for conducting a Quantitative Risk Assesment (QRA) to evaluate dermal sensitization. The in vitro GARDskin assay was recently adopted by the OECD (TG 442E) for the hazard identification of skin sensitizers. Continuous potency predictions are derived using a modified protocol that incorporates dose-response measurements. Linear regression models have been developed to predict human NESIL values. The aim of the study was to evaluate the precision and reproducibility of the continuous potency predictions from the GARDskin Dose-Response (DR) assay and its application in conducting QRA for fragrance materials using a Next Generation Risk Assessment (NGRA) framework. Results indicated that the GARDskin Dose-Response model predicted human NESIL values with a good degree of concordance with published NESIL values, which were also reproducible in 3 separate experiments. Using Isocyclocitral as an example, a QRA was conducted to determine its safe use levels in different consumer product types using a NGRA framework. This study represents a major step towards the establishment of the assay to derive NESIL values for conducting QRA evaluations for fragrance materials using a NGRA framework.
More Related Videos
06:21Diffuse Optical Spectroscopy for the Quantitative Assessment of Acute Ionizing Radiation Induced Skin Toxicity Using a Mouse Model
Published on: May 27, 2016
06:25Author Spotlight: High-Throughput Toxicity Screening Using Zebrafish Embryo Startle Response Assay
Published on: January 12, 2024
Related Concept Videos
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Spinal Cord Injury ll: Pathophysiology
Secondary Spinal Cord Injury llI: Pathophysiology